|
Collaborative Arrangements (Details)
|
12 Months Ended | 1 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
USD ($)
|
Dec. 31, 2010
USD ($)
|
Dec. 31, 2009
USD ($)
|
Dec. 31, 2007
PARI GmbH [Member]
USD ($)
|
Dec. 31, 2011
Roche [Member]
USD ($)
|
Dec. 31, 2010
Roche [Member]
USD ($)
|
Dec. 31, 2009
Roche [Member]
USD ($)
|
Dec. 31, 2011
Japan Tobacco Inc. [Member]
USD ($)
|
Dec. 31, 2008
Japan Tobacco Inc. [Member]
USD ($)
|
Dec. 31, 2006
Japan Tobacco Inc. [Member]
USD ($)
|
Dec. 31, 2011
Glaxo Smith Kline Inc. [Member]
USD ($)
|
Dec. 31, 2010
Glaxo Smith Kline Inc. [Member]
USD ($)
|
Dec. 31, 2009
Glaxo Smith Kline Inc. [Member]
USD ($)
|
Dec. 31, 2008
Glaxo Smith Kline Inc. [Member]
USD ($)
|
Dec. 31, 2007
Glaxo Smith Kline Inc. [Member]
USD ($)
|
Dec. 31, 2006
Glaxo Smith Kline Inc. [Member]
USD ($)
|
Dec. 31, 2004
Glaxo Smith Kline Inc. [Member]
USD ($)
|
Dec. 31, 2002
Glaxo Smith Kline Inc. [Member]
USD ($)
|
Dec. 31, 2011
Astellas US LLC and Astellas Pharma US, Inc. [Member]
USD ($)
|
Dec. 31, 2010
Astellas US LLC and Astellas Pharma US, Inc. [Member]
USD ($)
|
Dec. 31, 2009
Astellas US LLC and Astellas Pharma US, Inc. [Member]
USD ($)
|
Jul. 31, 2009
Tibotec Pharmaceuticals [Member]
USD ($)
|
Jul. 31, 2009
Tibotec Pharmaceuticals [Member]
EUR (€)
|
Dec. 31, 2011
Tibotec Pharmaceuticals [Member]
USD ($)
|
Dec. 31, 2011
Tibotec Pharmaceuticals [Member]
EUR (€)
|
Dec. 31, 2010
Tibotec Pharmaceuticals [Member]
USD ($)
|
Dec. 31, 2010
Tibotec Pharmaceuticals [Member]
EUR (€)
|
Dec. 31, 2009
Tibotec Pharmaceuticals [Member]
USD ($)
|
Dec. 31, 2009
Tibotec Pharmaceuticals [Member]
EUR (€)
|
Dec. 31, 2005
Up-front Payment [Member]
Japan Tobacco Inc. [Member]
USD ($)
|
Dec. 31, 2011
Fourteen Percentage Of Royalty Payable As Net Sales [Member]
USD ($)
|
Dec. 31, 2011
Eighteen Percentage Of Royalty Payable As Net Sales [Member]
USD ($)
|
Dec. 31, 2011
Twenty Two Percentage Of Royalty Payable As Net Sales [Member]
USD ($)
|
Dec. 31, 2008
Ranexa Product [Member]
Roche [Member]
USD ($)
|
Dec. 31, 2006
Ranexa Product [Member]
Roche [Member]
USD ($)
|
Dec. 31, 2009
Hepsera Product [Member]
Glaxo Smith Kline Inc. [Member]
USD ($)
|
Dec. 31, 2008
Hepsera Product [Member]
Glaxo Smith Kline Inc. [Member]
USD ($)
|
Dec. 31, 2007
Hepsera Product [Member]
Glaxo Smith Kline Inc. [Member]
USD ($)
|
Dec. 31, 2011
Volibris Product [Member]
USD ($)
|
Dec. 31, 2010
Volibris Product [Member]
USD ($)
|
Dec. 31, 2009
Volibris Product [Member]
USD ($)
|
Dec. 31, 2011
Volibris Product [Member]
Glaxo Smith Kline Inc. [Member]
USD ($)
|
Dec. 31, 2011
Lexiscan Product [Member]
Astellas US LLC and Astellas Pharma US, Inc. [Member]
USD ($)
|
Dec. 31, 2010
Lexiscan Product [Member]
Astellas US LLC and Astellas Pharma US, Inc. [Member]
USD ($)
|
Dec. 31, 2009
Lexiscan Product [Member]
Astellas US LLC and Astellas Pharma US, Inc. [Member]
EUR (€)
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||
| Total assets held by the joint venture with BMS | $ 1,620,000,000 | $ 1,450,000,000 | |||||||||||||||||||||||||||||||||||||||||||
| Total liabilities held by the joint venture with BMS | 1,270,000,000 | 759,500,000 | |||||||||||||||||||||||||||||||||||||||||||
| Amount paid to reduce the royalty rate | 13,500,000 | ||||||||||||||||||||||||||||||||||||||||||||
| Research and development expense | 16,000,000 | 7,000,000 | 5,000,000 | 24,700,000 | 17,900,000 | 22,100,000 | 17,900,000 | 52,400,000 | 35,700,000 | 15,000,000 | |||||||||||||||||||||||||||||||||||
| Percentage of royalty payment | 14.00% | 18.00% | 22.00% | ||||||||||||||||||||||||||||||||||||||||||
| Net sales of third party | 200,000,000 | 200,000,000 | 400,000,000 | ||||||||||||||||||||||||||||||||||||||||||
| Royalty revenues | 268,827,000 | 545,970,000 | 491,818,000 | 75,500,000 | 386,500,000 | 392,700,000 | 39,700,000 | 48,000,000 | 32,400,000 | 9,900,000 | 10,200,000 | 9,400,000 | 51,300,000 | 43,200,000 | 19,700,000 | ||||||||||||||||||||||||||||||
| Payment in accordance with agreement | 9,000,000 | 11,000,000 | |||||||||||||||||||||||||||||||||||||||||||
| Number of years amortized over its useful patent life | 11 | ||||||||||||||||||||||||||||||||||||||||||||
| Up-front payment received | 20,000,000 | 10,000,000 | |||||||||||||||||||||||||||||||||||||||||||
| Milestone payments received | 20,000,000 | 11,000,000 | 10,000,000 | 17,000,000 | 10,000,000 | ||||||||||||||||||||||||||||||||||||||||
| Sales limit for achievement | 75,000,000 | 100,000,000 | |||||||||||||||||||||||||||||||||||||||||||
| Deferred revenue recognized | 24,500,000 | 3,400,000 | 3,600,000 | 9,800,000 | 8,700,000 | 8,300,000 | |||||||||||||||||||||||||||||||||||||||
| Future milestone receivables | 80,000,000 | ||||||||||||||||||||||||||||||||||||||||||||
| Research and development reimbursement contract maximum | $ 100,000,000 | € 71,500,000 | |||||||||||||||||||||||||||||||||||||||||||